A “maturity curve” can help organizations move engagement beyond performative gestures to a strategic asset.
Amy Dorgan
Advertisement
Amy Dorgan is a healthcare strategist with more than 20 years of experience bringing innovative therapies and technologies from concept to market. Throughout her career across pharmaceutical, biotech, and medical device companies, Amy has championed approaches that place patient needs at the center of innovation, commercialization, and care delivery.
Articles by Amy Dorgan
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: GSK Acquires Trispecific T Cell-Engager from Chimagen, Sanofi & Cheplapharm Form Strategic Partnership
2
Boards, AI, and 500 Years of Experience in Life Sciences: Takeaways from the 2026 Life Sciences Board Forum
3
Novo Nordisk Rebranding to'Novo'
4
Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership
5